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Abstract 
Introduction: Adult onset Still’s disease (AOSD) is an uncommon systemic 
inflammatory disease on the clinical spectrum of autoinflammatory disorders. Its 
presentation and clinical course may result in several well differentiated phenotypes: 
from a systemic and highly symptomatic pattern to a chronic articular pattern. 
Overproduction of numerous pro-inflammatory cytokines is observed in AOSD. 
Anakinra (ANK), a human interleukin (IL)-1R antagonist, has recently been approved 
in the EU for the treatment of AOSD. 
Areas covered: In this review, we discuss the main studies on the efficacy and safety 
on ANK for the treatment of AOSD. The vast majority of them are retrospective studies 
and case series. 
Expert commentary: Overall, ANK is an effective biologic agent for the treatment of 
AOSD, especially for the systemic pattern and also for those patients who have life-
threatening complications, which frequently occur over the course of the disease. The 
initial dose usually indicated of ANK in adults is 100 mg/day subcutaneously, although 
dose reduction can be performed in some cases once the disease is under control. The 
safety profile of ANK is favorable and similar to that described in other rheumatic 
diseases. In conclusion, ANK is an effective and safe agent for the treatment of AOSD. 
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Adult-onset Still´s disease (AOSD) is a rare systemic inflammatory disease of unknown 
origin affecting mainly young people with an estimated annual incidence between 0.16 
and 0.4/100,000 persons worldwide, independently of ethnic group [1-3]. AOSD is 
slightly more common in women [4,5]. Typically, there is a bimodal age distribution, 
with one peak between 15 and 25 years and the other one between 35 and 45 years [1].  
AOSD and systemic onset juvenile idiopathic arthritis (SJIA) are considered two faces 
of the same disease starting at different ages. However, the majority of authors actually 
consider that AOSD may be categorized as a multigenic autoinflammatory disorder at 
the crossroads of autoinflammatory and autoimmune diseases, due to its complex 
pathogenesis, involving both innate and adaptive immune system [3]. 
The etiology of AOSD is unknown. Infectious and other environmental factors trigger a 
systemic autoinflammatory response in genetically predisposed individuals leading to a 
dysregulation of the inflammasome complex with the overproduction of numerous pro-
inflammatory cytokines such as interleukin (IL)-1, IL-6, IL-18, interferon (IFN)-γ and 
tumor necrosis factor (TNF)-α [6,7]. Cases of AOSD associated with malignancies have 
also been described but this association is not common [8,9]. 
AOSD is clinically characterized by daily high spiking fever, evanescent maculopapular 
skin rash, arthritis, musculoskeletal symptoms, sore throat and hepatosplenomegaly. 
Other common manifestations include pharyngitis, lymphadenopathy, pulmonary 
infiltrates, pleuritis, pericarditis, myocarditis and abdominal pain [3,10,11]. The 
presence of nonspecific laboratory findings is the result of a systemic inflammatory 
response. Patients present elevation of acute-phase reactants, such as erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP), marked leukocytosis with 









and aspartate aminotransferases. Serum ferritin levels are particularly increased in 
AOSD (typically more than 5 times above the high limit of normal) and it may be a 
good marker of disease activity [3,11]. AOSD is also associated with a reduction in the 
glycosylated ferritin fraction, so that the combination of serum ferritin levels higher 
than 1000 µg/L with a glycosylated fraction under 20% has been found to have a high 
specificity for a diagnosis of AOSD [12,13]. 
The presentation and clinical course of AOSD may result into three well differentiated 
phenotypes: a monophasic or monocyclic AOSD, characterized by a unique and self-
limited flare lasting several weeks to months with subsequent resolution (30% of cases); 
a systemic intermittent pattern characterized by recurrence of multiple flares with/ 
without joint symptoms (30% of cases) and a chronic articular pattern, characterized by 
persistent polyarthritis with progressive joint destruction (around 40%) [3,7,9]. Life-
threatening complications, with a high mortality rate, appear in around 15-20% of 
patients with AOSD [8,14]. Among them, the macrophage activation syndrome (MAS) 
or reactive hemophagocytic syndrome (RHS) is the most severe complication [14]. 
Treatment of AOSD has been based on data from single clinical reports or small 
retrospective case series studies. Non-steroidal anti-inflammatory drugs (NSAIDs) and 
glucocorticoids (GC) represent the first line therapy, particularly for musculoskeletal 
manifestations and fever, with response rates around 20% and 60% respectively 
[3,10,15]. However, about 40-45% of patients with AOSD develop glucocorticoid-
dependence and mild or severe long-term side effects [16]. As a result, disease-
modifying anti-rheumatic drugs (DMARDs) such as methotrexate (MTX), azathioprine 
(AZA) or leflunomide (LEF), are often required as second line therapy [15-17]. In 
refractory cases to these treatments, biologic drugs, particularly anti-IL-1 and anti-IL-6 









complications [3,18,19,20]. Anti-IL-6R [21-24] and TNF-α blocking agents 
[3,15,19,20] have also shown to be useful in AOSD presenting with severe joint 
involvement [18]. In patients who are refractory to these therapies or in those with life-
threatening complications other therapies such as: intravenous immunoglobulin, 
cyclosporine A, cyclophosphamide or plasma exchanges can be used [3,8,10] (Figure 
1).  
Here, it is interesting to highlight the potential role of the IL-1 inhibitors (IL-1-INH) 
including anakinra (ANK), canakinumab (CAN) and rilonacept in the management of 
refractory systemic and articular clinical patterns of AOSD [25,26-30]. Anakinra is a 
recombinant, non-glycosylated, form of human IL-1R antagonist. Since it has a very 
short half-life, daily subcutaneous administrations are necessary. In contrast, CAN is a 
human anti-IL-1β monoclonal antibody with a longer half-life which can be 
administered every 8 weeks, while rilonacept (also known as IL-1 Trap) is a dimeric 
fusion protein that neutralizes IL-1 which is administered once a week. Recently, the 
European Commission (EC) has approved an extension of the indication for ANK 
(Kineret®) to encompass the treatment of Still’s disease, including SJIA and AOSD, in 
all 28 European Union (EU) member states 
(https://www.sobi.com/en/investors/kineretr-anakinra-approved-eu-treatment-stills-
disease). 
In the present review we discuss the main clinical studies performed to date that have 
led to the approval of ANK for the treatment of AOSD.     
 
2. Unmet needs in AOSD management 
Due to the low prevalence of AOSD, there are still many concerns regarding diagnosis, 









Because of that, in the clinical practice the diagnosis of AOSD is usually made by 
exclusion of other systemic diseases. Currently, the more commonly used criteria are 
those proposed by Yamaguchi et al. [31] and Fautrel et al. [32] (Table 1). The most 
common index used to monitor the course of the disease is the Pouchot´s activity score 
[33]. Recently a new index known as “Relapsing Polychondritis Disease Activity 
Index” [34], in which 27 items are evaluated in a weighted way up to a total of 265 
points according to the clinical situation in the 28 days prior to each assessment, has 
been proposed [34]. However, simpler indices that can be applied to daily clinical 
practice are still required. It is especially true since the advent of biologic agents that are 
now available for the management and control of this disease. With respect to this, until 
recently there were no specific treatment approved for this condition so the management 
of AOSD was considered empirical. Most information on therapy, in particular that 
related to the use of biologic agents, is retrospective what makes it difficult to interpret. 
On the other hand, ANK has not yet approved by the FDA for the indication of AOSD 
in the USA, where they have requested the realization of a clinical trial that is currently 
in progress (ClinicalTrials.gov Identifier: NCT03265132). 
 
3.  Anakinra (ANK): main pharmacologic characteristics 
IL-1 is a pivotal pro-inflammatory cytokine that mediates many cellular responses in 
AOSD and in other auto-inflammatory diseases [6,7]. ANK is a non-glycosylated 
human interleukin-1R antagonist (IL-1ra) produced in Escherichia coli cells by 
recombinant DNA technology. It neutralizes the biologic activity of IL-1α (IL-1α) and 
IL-1β (IL-1β) by competitively inhibiting their binding to interleukin-1 type I receptor 
(IL-1RI) [35]. This biologic agent was used in patients with rheumatoid arthritis (RA) 









adolescents, children and infants aged 8 months and older with cryopyrin-associated 
periodic syndromes (CAPS), including neonatal-onset multisystem inflammatory 
disease (NOMID)/chronic infantile neurological, cutaneous, articular syndrome 
(CINCA), Muckle-Wells syndrome (MWS) and familial cold autoinflammatory 
syndrome (FCAS) [35-40]. In April 2018, the use of ANK (Kineret®) was approved by 
the EC for the treatment of Still’s disease including SJIA and AOSD encompassing a 
spectrum of indication in adults, adolescents, children and infants aged 8 months and 
older with a body weight ≥10 kg. In these cases, ANK can be administered as 
monotherapy or in combination with NSAIDs and/or DMARDs 
(https://www.sobi.com/en/investors/kineretr-anakinra-approved-eu-treatment-stills-
disease). 
The recommended dose in AOSD for patients weighing 50 kg or more is 100 mg/day by 
subcutaneous administration. Dose must be given according to weight in those patients 
weighing less than 50 kg with a starting dose of 1-2 mg/kg/day. ANK is eliminated by 
glomerular filtration and subsequent tubular metabolism. Consequently, plasma 
clearance of ANK decreases with reductions of renal function No dose adjustment is 
needed for patients with creatinine clearance [CrCl] between 60 to 89 ml/min. However, 
it should be used with caution in patients with moderate renal impairment (CrCl 
between 30 and 59 ml/min). Administration of ANK every other day can be used in 
patients with severe renal deficiency (CrCl <30 ml/min) or end stage renal disease, 
including dialysis. Although no dose adjustment is required for patients with moderate 
hepatic impairment, it should be used with caution in patients with severe hepatic 
insufficiency [35].  
Information on ANK therapy in elderly people is scarce. It comes from the RA field. 









years of age, were included in several clinical trials [35]. Overall, no differences in 
safety or effectiveness were observed between those ≥ 65 years and the remaining 
patients. Nevertheless, since there is a higher incidence of infections in the elderly 
population in general, we think that we have to be especially careful at the time of 
prescribing ANK in elderly people. There is also limited information on the use of ANK 
in pregnant and lactating women. With respect to this, animal studies do not indicate 
reproductive toxicity. Nonetheless, ANK is not recommended in during pregnancy or in 
women of childbearing age not using contraception. This agent is contraindicated in 
patients with hypersensitivity to the active substance or to any of its excipients or to E. 
coli derived proteins. Furthermore, ANK treatment must not be initiated in patients with 
neutropenia (neutrophils <1.5 x 109/l) [35].  
Additional information about the contraindications and adverse effects of ANK are 
shown in Table 2. Special mention deserves the so-called MAS. Patients with AOSD 
have an increased risk of spontaneous development of MAS [3,11,14]. Nevertheless, 
during post-marketing use of ANK, case reports of MAS in ANK treated patients with 
AOSD have also been reported. Nonetheless, a causal relationship between ANK and 
MAS has not been established yet. 
Regarding immunogenicity, the occurrence of antibodies was typically transient and not 
associated with clinical adverse reactions or loss of efficacy. In a study in patients with 
CAPS, the majority of patients developed ANK anti-drug antibodies [25]. However, it 
was not associated with any clinically significant effects on pharmacokinetics, efficacy, 
or safety [41]. Currently, there is not available data on the incidence of neutralizing 
antibodies in patients with AOSD treated with ANK. 
 









As mentioned above, IL-1β is one of the crucial cytokines involved in the pathogenesis 
of AOSD. In consequence, it is one of the main targets in the treatment of this condition 
[6,7,28]. Three IL-1β antagonist agents are currently available: ANK, CAN and 
rilonacept. Among them, ANK has been the most widely used anti-IL1β agent in 
patients with AOSD, including a randomized open-label study [42], another prospective 
open-label study [43], multiple retrospective studies and case series, and more than 80 
case reports [44-47].  
The first cases of ANK-treated AOSD refractory to other therapies were reported in 
2003-2005 [44,45,48]. In 2007, two studies including 8 patients in total showed good 
efficacy of ANK in patients with AOSD presenting with systemic symptoms refractory 
to glucocorticoids, DMARDs and TNF-α inhibitors. Interestingly, the symptoms 
disappeared in a few days after the first ANK administration and the inflammatory 
markers returned to normal levels in 2-4 weeks. ANK therapy also allowed a fast GC 
tapering, although relapses occurred a few days after discontinuation of this therapy 
[46,47].  
Tables 3 and 4 show the main prospective and retrospective studies on ANK in the 
treatment of patients with AOSD that are discussed in the next sections. 
 
4.1 Prospective, randomized, active-controlled, open-label studies (Table 3)  
To our knowledge, there is only one multicenter, randomized, active-controlled, open-
label study assessing the efficacy and safety of ANK in patients with AOSD from 10 
centers located in Finland, Norway, and Sweden. Patients were evaluated at 8 and 24-
weeks of follow-up, with an open-label extension phase of 28 weeks (until week 52) 
[42]. The study compared the efficacy of ANK with that of conventional DMARDs, 









the Yamaguchi´s criteria [31] (Table 1). All the patients had been refractory to GC and 
DMARDs, defined as of presence active disease in spite of receiving prednisolone ≥10 
mg/day with/without concomitant DMARD or glucocorticoids plus a DMARD for ≥2 
months prior to randomization. The primary endpoint was remission defined as no fever 
in the absence of NSAIDs, decrease of CRP and ferritin levels to reach the normal 
range, and normal swollen and tender joint counts, after 8 weeks of treatment. All the 
patients initially received prednisolone≥10 mg/day and along with NSAIDs if required. 
ANK was subcutaneously administered at a dose of 100 mg/day [42]. 
 
Twelve patients were randomized to ANK and 10 to DMARD (6 MTX, 2 AZA, and 2 
LEF) treatment. Patient groups were comparable at baseline, except for ferritin levels 
and prednisolone dose, which were significantly higher in the ANK group. At the time 
of inclusion in the study the mean [standard deviation (SD)] age of patients in the ANK 
and DMARD groups was 39 (18) and 39 (17) years, respectively; the median (range) 
disease duration was 14 (2-240) and 19 (3-204) months in the ANK and DMARD 
groups, respectively (Table 3). ANK treated patients achieved remission more 
commonly than those receiving conventional DMARDs. Seven of 12 patients from the 
ANK group reached remission vs 5 of 10 patients from the DMARD group at 8 weeks. 
Also, 6 of 12 patients undergoing ANK therapy were in remission versus 2 of 10 
patients on DMARDs group at week 24 [42]. Although differences did not reach 
statistical significance, more patients undergoing ANK therapy experienced 
improvement on physical health, as measured by the Medical Outcomes Study Short-
Form 36 (SF-36), than those from the DMARD group. However, both ANK and 
conventional DMARD therapy allowed to perform a reduction of prednisolone dose at 









The study included a 28-week open-label extension phase. In this period of time 
switching or add-on treatment with the comparator drug was allowed if improvement 
had not occurred within the 24 weeks of the randomized phase. This extension phase 
was completed by 17 patients. At week 52, 8 of 9 patients initially treated with ANK as 
monotherapy persisted on treatment with this biologic agent whereas 1 of these 9 
patients required MTX along with ANK. Among the 8 patients initially treated with 
DMARDs, 3 required additional therapy with ANK, 1 had to be switched to ANK in 
monotherapy and another to infliximab. Finally, at the end of the extension phase (week 
52), 7 of the 14 patients treated with ANK alone or in combination with DMARDs and 
2 of 3 on DMARD alone were in remission [42] (Table 3). 
With respect to safety, 3 patients experienced serious adverse events (AEs) during the 
randomized phase, with worsening features of AOSD in 1 patient under ANK therapy 
and in 2 patients on DMARDs. Other AEs included flu-like symptoms, diarrhea, and 
myalgias. Injection site reactions (ISRs) were reported by 8 patients receiving ANK. 
Four additional patients reported ISR during the study extension phase. 
Overall, the authors concluded that ANK induced more beneficial responses than 
DMARDs in patients with refractory AOSD [42]. 
Lequerré et al. studied the efficacy and safety of ANK treatment (100 mg/day) in 15 
patients (4 men/11 women) with AOSD diagnosed according to the Yamaguchi´s 
criteria [43]. At the time of ANK initiation, the patients’ mean age was 38.1±12.8 years 
(range: 22-62), the mean disease duration was 7.8±6.4 years (r: 2-27), and the mean 
duration of GC treatment 4.6 years. DMARDs had been used in all patients and were 
reported as ineffective or not very effective. The mean follow-up time (range) from the 
onset of ANK therapy to the last follow-up was 14.3 months (r: 11-27). A rapid 









assessment of pain, global assessment of disease activity, ESR, and CRP levels was 
observed in 11 of 15 patients (73%). Nine of these 11 patients achieved complete 
response (defined as a resolution of systemic symptoms and an improvement of the 
American College of Rheumatology [ACR] score ≥ 50%) at 3 months and also at last 
follow-up, and 2 had a partial response (defined as a resolution of systemic symptoms 
and an improvement of the ACR score by at least 20% but less than 50%) at 3 months 
and at the end of follow-up [43]. GC were discontinued in 2 of the 12 patients who were 
receiving this therapy at the onset of ANK treatment, and the GC dose was decreased in 
a range between 45% and 95% in 8 patients. Among the 12 patients initially receiving a 
DMARDs (MTX in 10) in combination with ANK, 7 continued receiving MTX and 1 
changed to another DMARD [43]. 
Four patients discontinued ANK treatment, 2 due severe skin rash at 1 and 3 months, 
respectively, and 2 due to lack of efficacy. Other transient AEs were bronchitis, 
uncomplicated hepatitis A, varicella, a cutaneous infection after a piercing, 
osteonecrosis of the femoral hip, and pain at the injection site. One case of MAS leading 
to transient ANK withdrawal was also recorded [43]. 
 
4.2. Case series and retrospective studies of patients treated with ANK (Table 4) 
This section includes retrospective studies and case series with at least 3 AOSD patients 
treated with ANK (Table 4). 
The most important is a retrospective, nationwide, cross-sectional, observational study, 
which showed data from 140 Italians (93 women and 47 men) diagnosed with AOSD 
according to the Yamaguchi´s criteria [25]. Patients were treated with ANK after failure 
to NSAIDs and immunosuppressive drugs, GC and DMARDs, and in some cases to 









after the onset of ANK therapy. Seventy-four percent of the patients had the systemic 
disease (SD) pattern and 26% the chronic articular disease (CAD) pattern. The mean 
disease duration before ANK onset was 4.2±6.8 years. At baseline, 98% and 86% of 
patients received steroids and DMARDs, respectively. ANK was started as a first-line 
biologic in 79% of patients and it was prescribed in combination with DMARDs in 
76%, being MTX the first choice DMARD used in association with ANK in 71% of the 
cases [25]. The initial ANK dose was 100 mg/day in 91% of patients. Higher doses 
(150-200 mg/day) were administered to 4 patients who presented with a very aggressive 
systemic form of the disease, and lower doses (50 mg/day or 100 mg every other day) in 
9 patients because tolerance problems. After 3, 6, and 12 months of follow-up, 118 
(84%), 109 (78%), and 97 (69%) patients were still receiving ANK, respectively. 
Overall, the mean duration of ANK treatment was 35.7±36.1 months. At the time of 
data analysis, 69/140 (49%) patients were still receiving ANK. The reasons for ANK 
discontinuation in the other 71 patients were the occurrence of AEs (34% of the 71 
cases), remission (sustained disappearance of all clinical and serological manifestations 
in 28%), primary inefficacy (23%), and secondary inefficacy (15%) [25] (Table 4).  
Regarding severity, the Pouchot’s score significantly decreased from 5.5±1.9 (range 2-
10) at baseline to 1.1±1.4 (range 0-7) after 3 months of treatment (p<0.0001). The 
analysis of the prevalence of the disease’s main clinical features and laboratory 
abnormalities at 3, 6, and 12 months showed a significant reduction in all these 
parameters (p<0.0001). Serum ferritin levels were significantly reduced at 3 months 
compared to baseline, and reduction of CRP and ESR was also observed. The 
percentage of patients with hepatomegaly or increased liver enzymes decreased from 
47% at baseline to 9% and 5% after 3 and 12 months of ANK treatment, respectively. 









33% and 14% after 3 and 12 months of ANK treatment, respectively. No differences in 
the clinical or serological response to treatment were identified when the patients were 
stratified according to age, sex, or disease phenotype (systemic or CAD pattern), or 
when comparing administration of ANK with or without concomitant DMARDs. The 
authors concluded that ANK was effective in reducing all AOSD-linked clinical and 
serological manifestations [25]. 
Primary and secondary inefficacy after 12 months of treatment were reported in 15 of 
140 (11%) and 11 of 140 (8%) patients, respectively. Twenty patients (14%) 
experienced complete remission and could discontinue ANK. Overall, ANK treatment 
allowed to reduce significantly the use of concomitant GC and DMARDs. In this 
regard, the proportion of patients receiving concomitant GC treatment decreased from 
98% at baseline (mean prednisone dose 77.6±186.3 mg) to 86% at 3 months (mean 
prednisone dose 8.8±11.2 mg), 56% at 12 months (mean prednisone dose 3.4±4.8 mg), 
and 32% at last follow-up. The percentage of patients receiving concomitant DMARD 
therapy also decreased from 86% at baseline to 51% at last visit [25].  
Twelve (8.5%) patients showed signs of MAS before initiation of ANK, and 5 patients 
suffered a MAS during ANK treatment: two of them recovered without discontinuation 
of the therapy, one patient recovered and then ANK treatment was restarted while 
another two died, one after 12 months and the other after 16 months of treatment [25].    
Other AEs were reported in 40 of 140 patients and they mainly consisted of in situ 
(n=28) or diffuse (n=12) local reactions, usually in the form of cutaneous urticarial 
lesions. Severe skin reactions led to ANK discontinuation in 18 cases. Seven infectious 
events occurred (3 cases of pneumonia, 3 cases of urinary tract infections, and 1 case of 









Vitale et al. performed a multicenter, retrospective, observational study on the use of the 
IL-1-inhibitor ANK in 78 patients with AOSD seen between January 2008 and July 
2016 [49]. Complete response was found in 78% of patients (61/78), and partial 
response in 13% (10/78); while treatment failure was reported in 9% of the patients 
(7/78). GC were given concomitantly in 66 cases (81%) and DMARDs in 32 cases 
(39.5%). Pneumonia was reported in 2 and lower limb ulcers in 1 of the patients [49] 
(Table 4). In this study, normalization of inflammatory markers (ESR, CRP) and the 
absence of all previously identified signs and symptoms of AOSD were considered as 
criteria for a complete response, meanwhile partial response was indicated for patients 
with clinical improvement but not reaching the criteria for complete response. 
Treatment was labelled as failing when neither clinical nor laboratory improvements 
were observed [49]. 
ANK efficacy was assessed in another multicenter, retrospective, open-label study 
conducted in Spain. It included 41 patients with AOSD who had failed to standard 
immunosuppressive therapy and in 20 cases also to at least one biological agent (mainly 
anti-TNF-α agents) [50]. At the onset of ANK, the patients’ mean age was 34.4±14 
years and the median disease duration 3.5 years (interquartile range, IQR 2-6); 98% of 
patients were treated with GC. ANK was prescribed as monotherapy in 12 patients or 
combined with other traditional DMARDs in remaining 29 patients, usually with MTX 
(n=24). The initial ANK dose was 100 mg/day [50] (Table 4). 
ANK treatment led to rapid and sustained improvement of clinical and laboratory 
parameters. The leukocyte count as well as the CRP, ESR, and ferritin levels were 
significantly decreased after 1 month of therapy and remained decreased after 12 
months of treatment. The frequency of anemia also decreased from 56% at baseline to 









were more refractory than systemic manifestations; however, they decreased from 88% 
at baseline to 42% at 3 and 12 months of ANK treatment [50]. After one year of 
therapy, 22 patients were still receiving ANK at a dose of 100 mg/day, 3 were treated 
with ANK 100 mg/48h, 1 with ANK 100 mg/72h, and 1 patient received ANK every 
two weeks. Seven patients had discontinued ANK for lack of efficacy, 5 because of 
AEs, 1 because of sustained remission, and 1 due to pregnancy planning. The median 
dose of prednisone was reduced from 20 mg/day (IQR: 11.3-47.5) at ANK onset to 5 
mg/day (IQR 0-10) at 12 months. A significant GC sparing effect was already observed 
at 1 month of ANK treatment [50]. After a median follow-up of 16 months (IQR 5-50), 
the most common reported AEs were skin reactions (n=8), leading to ANK 
discontinuation in 2 cases. Main data of this study are shown in Table 4 [49]. 
Rossi-Semerano et al. reported off-label efficacy of ANK (100 mg/day) in 35 (23 
women/12 men) patients with AOSD included in a French national study [51]. 
Complete clinical response was achieved in 54% of them and partial response in 34%. 
The median duration of was 461 days. Reduction of concomitant therapy was reported 
in 25 patients. ANK was discontinued in 20 patients because of either persistent 
remission (n=1), lack or loss of efficacy (n=14), AEs (n=3), or patient request (n=2). 
Severe AEs were reported in 3 patients (pneumonia, varicella zoster virus infection, and 
MAS and infection in one each). Evaluation of ANK response was not standardized in 
this study [51] (Table 4). 
In a nationwide retrospective study conducted in France between 2009 and 2010, 
Giampietro et al. investigated the safety and long-term effect of ANK treatment in 28 
patients (ratio men/women=1:2) with AOSD refractory to NSAIDs, GC, and DMARDs; 
14 of them had previously received at least one biological agent [52] (Table 4). It is 









Lequerré et al. [43]. The mean age at the start of ANK treatment was 40.3 years and the 
mean disease duration 9.3 years. Thirteen (46%) patients had a predominantly CAD, 
while the others had a SD pattern. ANK was initially administered at a dose of 100 
mg/day (19 in combination with MTX). ANK was used as monotherapy in 6 patients. 
The main clinical characteristics of this population are shown in Table 4 [52]. 
In this study, all patients responded to ANK, with a rapid and sustained decrease in the 
GC dose. Prednisone was reduced in 15 (54%) patients, from a mean dose of 34±22 
mg/day at ANK initiation to 10±8 mg/day after 3 months. At last follow-up (mean 23 
months), 16 patients were still being treated with ANK: 4 had a partial response and 12 
were in complete remission. Twelve patients had discontinued ANK: 2 of them due to 
an insufficient response, 4 because AOSD flare after a period of complete remission, 2 
because of AEs, and 1 due to pregnancy planning [52]. 
In another retrospective study performed in Greece [53], the efficacy and safety of ANK 
was evaluated in twenty-five patients (13 men and 12 women, median age 32 [range: 
18-71] years, median disease duration 7 months) with Still’s disease (4 patients with 
SJIA, and 21 with adolescent or AOSD) (Table 4). All patients had active disease 
resistant to GC (n=17), DMARDs (n=4), or TNF-α inhibitors (n=4). Sixteen received 
ANK (100 mg/day) in combination with DMARDs (MTX in 13 cases), and 9 received 
ANK in monotherapy [53]. Oral methylprednisolone was given to 22 patients at a 
median dose of 4 mg/day (range: 0-26). ANK was administered for a median time of 15 
months (range: 1.5-71). Twenty patients had a follow-up time of at least 6 months and 
15 patients a follow-up time greater than one year. Complete response was defined as 
the whole resolution of all disease-related symptoms, except for joint erosions. Partial 
clinical or laboratory response was defined as improvement (≥10% when measurement 









resolution of disease activity [53] (Table 4). In this study, disease activity resolved 
completely in 21 of 25 patients (84%) within a few days (median time 0.2 months), and 
the response was maintained until the last visit in all but one patient. Furthermore, a 
complete response of all disease-related symptoms (clinical and laboratory) occurred 
within a median time of 3 months in 80% of patients, while partial clinical and 
laboratory improvement was shown in 12% and 16% of patients, respectively. The oral 
GC dose was significantly reduced throughout the study and 12 patients were able to 
wean from GC [53]. MTX was discontinued in 3 patients 5-8 months after remission 
was achieved. ANK was discontinued in 8 patients in complete remission; 2 relapsed 
one month after treatment withdrawal, and the remaining 6 were still in remission after 
a median time of 6.5 months (range: 1-60 months) of treatment discontinuation. The 
analysis of the disease outcome in patients receiving ANK in monotherapy or in 
combination with a DMARD revealed no significant differences in the number of 
responses or in drug-related AEs [53].  
Cavalli et al. retrospectively evaluated 20 patients with severe or refractory AOSD who 
did not respond to combination therapy with NSAIDs, GC and conventional DMARDs. 
They were eventually treated with at least one biological agent. Eight patients had a 
CAD course and 12 a SD course without chronic articular involvement [54]. Complete 
response was defined as the absence of articular and systemic manifestations of AOSD, 
with normalization of inflammatory markers (CRP and ESR) and with a ≥50% 
reduction of the GC dose for at least 2 months. Persistence of disease manifestations or 
the need for an additional dose of GC [prednisone ≥15 mg/day] within 2 months from 
the initiation of a biologic was classified as treatment failure [54]. 
ANK represented the first-line biologic therapy in 16 cases, and was ultimately used in 









after the onset of this therapy. In was especially true for the SD (11 complete responses 
from 12 patients; 1 patient did not respond). GC treatment was discontinued in 7 
patients treated with ANK and reduced (at least 25% dose reduction) in another 8. 
Discontinuation or tapering of MTX was also possible upon clinical response in 9 
patients receiving ANK. ISRs were reported in 2 patients receiving ANK [54](Table 4). 
In a series of patients treated with ANK, complete remission was achieved in the 11 
patients who received ANK as a first-line biologic, and in 1 of 2 patients who received 
ANK as a second-line biologic. No severe AEs were reported. A cutaneous rash was 
reported in one patient treated with ANK [55]. 
Another retrospective observational study was conducted by Iliou et al. [10]. Ten 
patients resistant to GC and DMARDs were treated with ANK 100 mg/day. Clinical 
remission and successful GC tapering were achieved in all of them.  No major adverse 
events were reported [10] (Table 4).   
In the chart review by Quartuccio et al, clinical and laboratory findings were evaluated 
in 36 patients with AOSD, 12 of whom were treated with biological agents for serious 
and/or refractory AOSD [56]. ANK was used in 10 of them, although only 3 patients 
were still being treated with ANK at last follow-up [56] (Table 4).   
Naumann et al. in Germany reported 8 consecutive patients with refractory AOSD 
treated with ANK [57]. At the time of ANK initiation, the patients’ median age was 42 
years (r: 26-66) and median disease duration was 37.5 months (r: 4-139). All of them 
had been treated with at least one DMARD (including MTX) and 6 with anti-TNF 
therapy without reaching a long-lasting effect. They were responsive to high-dose GC, 
but flares occurred when GC were reduced to moderate or low doses. In this study, the 
authors stated that introduction of ANK (100 mg/day) resulted in sustained remission in 









significant improvement in clinical symptoms such as rash and arthritis within a few 
hours of ANK initiation. Furthermore, ANK treatment allowed a rapid tapering of GC 
to low doses in all patients. Although erythema at the injection site was reported in 2 
patients, no severe AEs related to ANK were recorded [57] (Table 4).   
Six of 57 patients with AOSD assessed in a retrospective, observational study were 
treated with ANK (administered along with GC in 5) [16]. Four patients had polycyclic 
AOSD, and 2 chronic AOSD. ANK treatment led to remission in 5 of the patients after 
a mean follow-up of 27.8 months. One of the patients with polycyclic AOSD 
experienced disease recurrence after 11 months of ANK therapy and discontinued the 
treatment [16].  
In another study, the authors described 4 of 10 consecutive AOSD patients who 
required ANK (100 mg/day) because of refractory AOSD with persistent active disease 
despite treatment with high doses of GC [46]. Systemic symptoms disappeared within 
hours after the first ANK administration in all patients and laboratory values 
(inflammatory makers and liver enzyme levels) reverted to normal within 2-4 weeks. 
ANK treatment allowed GC dose tapering in all patients that were discontinued in 3 of 
them. Self-limiting injection site erythema was reported by all patients. No other AEs 
was recorded during the follow-up period (5-17 months) [46] (Table 4). 
Kötter et al. (Germany) reported another case series that included 4 patients, 3 
treatment-resistant AOSD patients and 1 with life-threatening disease [47]. All the 
patients achieved sustained remission upon ANK therapy (treatment duration 12-44 
months [47]. GC were discontinued in 1 patient and the dose tapered in another 2. 
Severe erythema at the site of injection was reported in 1 patient [47] (Table 4).   
Similar results were obtained in a case series from Canada, on 4 patients treated with 









in all 4, MTX in 3 and TNF- blockers in 2) [45]. The authors reported a rapid reduction 
(within hours to a few days after the first ANK administration) of disease activity, 
hematological parameters, and biochemical markers in the 4 patients. However, ANK 
discontinuation led to a rapid return of fever and a rise in inflammatory markers in 2 
patients, with resolution following ANK reintroduction [45]. 
In another review, Maria et al. also reported 8 patients with refractory AOSD, 4 of them 
with a systemic pattern of the disease, who underwent treatment with ANK. After a 
median treatment duration of 24 months (range 2-57), complete or partial remission was 
observed in all of them [58] (Table 4). 
Petryna et al. reported 3 patients with AOSD refractory to treatment with GC and 
DMARDs and treated successfully with another IL-1-INH, rilonacept (a long-acting IL-
1 Trap) [59]. Previously, all of them had been treated with ANK: In two of them with 
100 mg twice daily, achieving a partial response, whereas in the other failing to control 
the symptoms at ANK dose of 100 mg/day for 6 weeks. All 3 patients were eventually 
switched to rilonacept [59] (Table 4). 
Finally, Rech et al. described 3 patients with AOSD refractory to standard treatment 
(prednisolone and MTX) ANK and anti-TNF therapy. They eventually achieved 
remission after initiation of IL-6-blocking therapy. The authors did not mention any AE 
in relation to ANK treatment [60] (Table 4). 
Priori et al. reported 3 patients with AOSD who had severe joint involvement and were 
resistant to conventional treatment [61]. ANK treatment was started (100 mg/day) and 
led to improvement of joint involvement in all 3 patients (2 patients achieved an ACR50 
and 1 an ACR20 response). GC dose was reduced in all of them [61] (Table 4).   
As a limitation of this review, it is possible that some of the patients included in the 









Taken together, the results derived from most studies indicate that ANK in AOSD, 
either a monotherapy or in combination with DMARDs, yields beneficial effects with 
rapid clinical and laboratory improvement in most patients. The use of this biologic 
agent allows GC tapering. In general, the safety profile of ANK in patients with AOSD 
is consistent with the safety data gathered from the use of ANK in patients with RA. 
 
5. Conclusions  
ANK is a biologic agent that has recently been approved for the treatment of AOSD. 
Since AOSD is an uncommon condition, most data on ANK efficacy come from 
retrospective reports. In this article we have reviewed the main observational studies 
and series of cases published on the efficacy and safety of ANK in AOSD. Data from 
most studies support the efficacy of ANK, both in monotherapy or in combination, 
especially for the systemic form of the disease when it is refractory to other more 
conventional therapies. Generally, a rapid and beneficial effect is observed in most 
cases within a few days from the beginning of ANK, allowing to reduce the dose of GC 
in a high percentage of patients. Nevertheless, relapses of the disease are not uncommon 
when the dose of prednisone falls below 10 mg daily. The safety profile of ANK is 
similar to that described in other chronic inflammatory diseases in which this agent is 
more commonly used. It should be noted that the majority of studies on the topic carried 
out to date are of low quality, since they are mainly observational studies and case 
series. 
 
6. Expert commentary   
AOSD is a rare multisystemic inflammatory disease of unknown origin predominantly 









autoinflammatory disorders [62,63]. Several sets of classification criteria have been 
developed for its diagnosis, but they lack sufficient sensitivity and specificity to be 
applied for individual diagnosis in clinical practice. Currently, the criteria more 
commonly used are those proposed by Yamaguchi et al. [31] and Fautrel et al. [32]. 
Several clinical phenotypes have been recognized in AOSD: a systemic pattern and a 
CAD [7,8,64-66]. The systemic pattern may yield more serious and life-threatening 
complications in the short-term, but CAD is more devastating and disabling in the long-
term [14]. 
The ultimate goal in the management of AOSD is to control the outbreaks and to reach 
a sustained remission of the disease [3,11,67]. GC constitute the gold-standard therapy 
for the initial treatment of AOSD, leading to remission in around 60% of patients. 
Biologic therapy has to be considered in patients with AEs or in those in whom 
conventional therapy is not effective. Among the biologic agents currently available, IL-
1 and IL-6 neutralizing agents are those that have shown greater efficacy in a large 
number of patients [20,67,68].  
ANK, a non-glycosylated human IL-1R antagonist, is an effective drug for the treatment 
of AOSD, especially for the systemic pattern of the disease. Although there is only one 
randomized, active-controlled, open-label study and another prospective open-label 
study [42,43], multiple retrospective studies and case series support the utility of ANK, 
both in monotherapy or in combination, for the treatment of refractory AOSD, 
especially for the systemic pattern of the disease, and also as first line of therapy for 
those life-threatening complications such as MAS, disseminated coagulopathy or 
myocarditis. ANK yields beneficial effect in a few days or weeks and allows to taper 









The initial dose usually indicated of ANK in adults is 100 mg/day, although dose 
reduction by half or spacing the injection every other day or longer can be performed in 
some cases once the disease is under control. 
There is no unanimous consensus on the method of ANK withdrawal in patients who 
are in remission. While it is possible to discontinue ANK in some patients with well 
controlled disease, the possibility of relapses has to be kept in mind. Also, although 
ANK was proved to be effective for the treatment of MAS, several cases of MAS were 
reported in patients undergoing ANK treatment. In them, the causal relationship 
between MAS and AOSD has not been elucidated. It is important to remark that the 
safety profile of ANK is globally favorable and similar to that described in other 
rheumatic diseases [34]. Finally, the combination of several biologic agents is not 
recommended for the treatment of AOSD because it may increase considerably the risk 
of AEs without reaching greater efficacy, as occurs in other systemic diseases. 
 
7. Five-year view 
In the following years, a better definition of the AOSD phenotypes will be achieved. 
This fact will allow the clinicians to better identity those patients who would benefit of 
specific biologic agents. New biomarkers on molecules that seem to play a role in the 
pathogenesis of the disease will help us to monitor the disease allowing the clinicians to 
measure the risk of relapses of the disease [69-71]. It may be the case of calprotectin 
[72]. 
Since Kineret® (ANK) has been approved in the EU for the treatment of the disease, we 
expect that this therapy will be used more commonly, in particular in patients with a 
systemic disease (SD) pattern or in those with a refractory disease. The prompt use of 









associated to the disease. We foresee that the use of other molecules that also block IL-1 
such as canakinumab and rilonacept will be extended. Besides anti-IL-6R antagonists 
that are used in some patients, in particular in those with refractory disease or with 
predominant CAD pattern, other biologic agents that act blocking primordial cytokines 
involved in the pathogenesis of the disease, such as IFN-γ and IL-18, will be considered 
in some individuals with AOSD. 
 
Key issues 
• AOSD is a complex and heterogeneous disorder at halfway of autoinflammatory and 
autoimmune diseases.  
• Although the pathogenesis of AOSD remains unknown, some key pro-inflammatory 
cytokines (IL-1, IL-6, IL-18, TNFα, and IFN-ϒ) are considered to have a relevant role. 
• Glucocorticoids constitute the first line of treatment for AOSD. Conventional DMARD, 
in particular MTX, are often considered in refractory cases or as GC sparing agents.  
• Biologic agents must be considered in the management of AOSD refractory to GC and 
conventional DMARDs, since the ultimate goal in the management of AOSD is to 
achieve sustained remission and reduce the risk of relapses of the disease, avoiding life-
threatening complications. 
• ANK, a human IL-1R antagonist, is an effective biologic agent for AOSD. Data from 
multiple retrospective studies and case series demonstrate the efficacy of ANK, both in 
monotherapy or in combination, for refractory AOSD, especially for the systemic 
pattern and in patients who experience life-threatening complications of the disease.  
• Overall, the benefit/risk ratio and safety profile of ANK is favorable and similar to that 
described in other rheumatic diseases. Although the risk of relapses is high, withdrawal 
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Figure 1. Proposed work-up for the management of Adult-Onset Still's Disease. 
 
Abbreviations: ANK: anakinra; AOSD: adult-onset Still's disease; AZA: azathioprine; 
CAN: canakinumab; DMARDs: disease-modifying antirrheumatic drugs; GC: 
glucocorticoids; IL: interleukin; IFX: infliximab; LEF: leflunomide; NSAIDs: 
nonsteroidal anti-inflammatory drugs; RLN: rilonacept; TNF-α: tumor necrosis factor 
alpha; TCZ: tocilizumab; IV: intravenous. 











Yamaguchi´s classification criteria for diagnosis of AOSD 
 
Major criteria: 
1. Fever ≥ 39ºC lasting at least 1 week 
2. Arthralgia or arthritis  lasting ≥ 2 weeks 
3. Typical nonpruritic salmon-pink skin rash 
4. Leukocytosis ≥ 10,000/mm3 with  granulocytes ≥ 80%  
 
Minor criteria: 
1. Sore throat 
2. Lymph node enlargement 
3. Hepatomegaly or splenomegaly  
4. Abnormal liver function tests 




2. Malignancy (mainly malignant lymphoma) 
3. Other systemic disorders (mainly vasculitis) 
(≥ 5 criteria are required with at least 2 being major criteria and                           
no exclusion criteria) 
 
Fautrel´s classification criteria for diagnosis of AOSD 
 
Major criteria: 
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3. Transient erythema 
4. Pharyngitis 
5. Polymorphonuclear cells ≥ 80% 
6. Glycosylated ferritin ≤ 20% 
 
Minor criteria: 
1. Maculopapular rash 
2. Leukocytosis > 10,000/mm3 




















Abbreviations: AOSD: adult-onset Still´s disease; ANA: antinuclear antibodies;  













Abbreviations: MedDRA: Medical Dictionary for Regulatory Activities. 
Adverse reactions are listed according to MedDRA system organ class and frequency 
category. * Frequency categories are defined using the following convention: very 
common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare 
(≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from 
the available data). Most of the results shown in the table are obtained from placebo-
controlled studies performed in patients with rheumatoid arthritis and from open-label 
studies in patients with cryopyrin-associated periodic syndromes. $ Between uncommon 
and common depending on MedDRA and the clinical series published. 
MedDRA Organ System  Frequency* Undesirable Effects 
Skin and subcutaneous tissue 
disorders  
 
Very common  
Uncommon/common$ 
Injection site reaction  
Rash 
Nervous system disorders  Very common  Headache  
Metabolic disorders Very common  Blood cholesterol increased  




Bacterial infections  
(cellulitis, pneumonia, bone 
and joint infections) 
Opportunistic infections 
(fungal, mycobacterial, viral) 
Blood and lymphatic system 
disorders  
Common  Neutropenia  
Thrombocytopenia  
Immune system disorders  Uncommon  Allergic reactions including 
anaphylactic reactions, 
angioedema, urticaria and 
pruritus  
Hepatobiliary disorders  Uncommon  
 
Not known  
(cannot be estimated from  
the available data) 
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Table 3. Published randomized, controlled trial and prospective study of anakinra use in 
patients with adult-onset Still´s disease. 
Abbreviations: ANK: anakinra (IL-1R antagonist monoclonal antibody); DMARD: disease-
modifying anti-rheumatic drugs; F: female; FH: femoral hip; ISR: injection site reaction; M: 
male; MAS: macrophage activation syndrome; mo: month; NA: not available; NNS: number not 
specified; SAE: serious adverse event. 
1 As reported in the publication; assessment of response to treatment and definition of 
complete/partial/no response vary among studies, see text for more information on treatment 
response in each study. 
2 In patients treated with ANK and as reported in the publication. 
3 Nordic = Finland, Norway, Sweden. 
4 Patients included in this study were also identified for inclusion in the Giampietro 2013 
retrospective study [50], which is shown in Table 4. It is however not specified whether all or 
only a subset of these patients was included in Giampietro 2013 study [50]. 
*According to the publication, 12 patients received ANK treatment in the randomized phase, 9 
Study 
(Country) 










No response1  G
u
Prospective, randomized, active-controlled, open-label study  
Nordström 2012 





(6F, 6M)  
DMARD  
n=10  





24 weeks   
(total)  
8 weeks:  
58% (ANK)  
50% (DMARD)  
24 weeks:  
50% (ANK)  
20% (DMARD)  
NA  Worsening of 
AOSD:  















28 weeks  28 weeks:  




NA  NA  N





(11F, 4M)  
≤ 1 mo: n=2  
8-12 mo: n=5  
15-27 mo: n=8  
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of these patients continued ANK treatment in the extension phase, and 4 patients who received 
DMARD treatment in the randomized phase started ANK treatment in the extension phase. 
However, the authors also state that at 52 weeks 14 patients had ANK in monotherapy or 
ANK/DMARD in combination, with 7 out of 14 patients in remission. 
§ All treated with ANK. 
¶ Two out of 4 patients classified as non-responders here discontinued ANK after 1 and 3 
months because of a skin rash. 
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Table 4. Published case series and retrospective studies of anakinra use in patients with 

















Colafrancesco   




(93F, 47M)  
 
< 3 mo: n=22  
3-6 mo: n=9  
6-12 mo: n=12  




remission &  
ANK  
withdrawal  
in 14%)  
 
Lack /loss of  
efficacy at 12 
months:  
11% /8%  
 
Baseline: 98%  
At 12 mo: 56% 
















2015 (Spain)  
[50] $  
41  
(26F, 15M)  
< 3 mo: n=4  
3-6 mo: n=5  
6-12 mo: n=5  
≥ 12 mo: n=27  
NA  NA  Lack of  
efficacy  
at 12 mo:  
17%  









(23F, 12M)  
Median 15 mo  
(IQR 38 mo)  








(19F, 9M)  
< 3 mo: n=4  
At last follow-up 
(mean 23 mo): 
n=16 still 
receiving ANK  
57%  29%  Loss of 
efficacy:  
14%  
Dose reduced  




(Greece)7 [53]   
25  
(12F, 13M)  
Median 15 mo  
(range 1.5-71 mo; 
at least 6 months 
in 20 patients)  
80%  12%  Lack/loss of 
response:  
4% /4%  










(11F, 9M)  
3-6 mo: n=4  
16-36 mo: n=5  
48-66 mo: n=6  
72-102 mo: n=5  
70%  10%  20%  Dose  
reduced in 8  
Stopped in 7  
I
I




12 mo: n=2  
48-61 mo: n=6  
93-102 mo: n=3  
Unspecified: n=2  
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Iliou 2013 
(Greece)7 [10]   
10  
(NA)  
NA  Overall  
response:  
100%  
0%  Dose tapering     





10  NA  NA                       NA Lack/loss  
of response  









(7F, 1M)  
6-12 mo: n=4  
36-48 mo: n=4  
Overall  
response: 100%  
0%  Tapering to  








Mean follow-up  
28 months  












(1F, 3M)  
Range 5-17 mo  Overall  
response: 100%  
0%  Tapering in all  






(3F, 1M)  
12-15 mo: n=3  
44 mo: n=1  
Overall  
response: 100%  
0%  Tapering in 2/4  





(2F, 2M)  
Range 6-14 mo  Overall  
response: 100%  
0%           Stopped in 3/4  I
M
o




Median 24 mo 
(range 2-57 mo) 





6 weeks: n=1  
Unknown: n=2  





(2F, 1M)  
Range 1-6 mo   0%  0%  100%     NA  N




8 weeks: n=1  
12 mo: n=1  




0%  Dose  
reduced  
in all  
 Skin reaction  
 (n=1)  
Abbreviations: AEs: adverse events; ANK: anakinra (IL-1R antagonist monoclonal antibody); 
F: female; IQR: interquartile range; ISRs: injection site reactions; M: male; MAS: macrophage 
activation syndrome; mo: month; NA: not available; NR: not reported.  
1 As reported in the publication; assessment of response to treatment and definition of 
complete/partial/no response vary among studies. See text for more information on treatment 
response in each study; if the study does not specifically mention “complete” or “partial” 
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2 In patients treated with ANK and as reported in the publication; NR: no AE reported, however 
the absence of AEs is not clearly stated either. 
3 It is possible that some of the patients included in all the studies conducted in France and Italy 
had been reported in more than one study. However, as the publications do not specifically 
mention how many patients were already reported, and in what studies, it is not possible to 
clearly identify the extent of redundant reporting. For more information on the studies included 
in this Table see commentaries in the text. 
4 Considering the nationwide/multicentre and retrospective nature of the studies by Vitale 2016 
[49] and Rossi-Semerano 2015 [51], it is probable that they include some or all of the patients 
already reported in Dall’Ara 2016 [55], Cavalli 2015 [54], Quartuccio 2012 [56], and Priori 
2008 [61]; and Gerfaud-Valentin 2014 [16] and Maria 2014 [58], respectively. 
5 The Rossi-Semerano 2015 study [51] includes more patients with AOSD than the Giampietro 
2013 study [52]. However, as the Giampietro 2013 study [52] focuses solely on AOSD patients 
and provides more detailed data on patient population and outcomes, it is presented as the main 
retrospective study for France. 
6 Some of the patients included in Lequerré 2008 study [43] (Table 3) were identified for 
inclusion in the Giampietro 2013 retrospective study [52]. It is however not specified whether 
all or only a subset of these patients were included in Giampietro 2013 study [52]; mean follow-
up in Lequerré 2008 study [43] was 14 months, versus 23 months in Giampietro 2013 study 
[52]. 
7 The Greek and German studies shown in this table were conducted at different hospitals in 
different cities and therefore likely present non-overlapping patient populations. 
$ Both the Colafrancesco [25] and Ortiz-Sanjuán [50] studies report the proportions of patients 
experiencing a lack or loss of efficacy but do not clearly state the proportion of patients with 
response to ANK treatment. 
* Other adverse events are reported in the overall study, however the diagnosis of the patients in 
whom these adverse events occurred is not specified. 
§ Clinical response; data not available in 1 patient; besides reporting the clinical response rates, 
the authors also indicate that 14 (40%) patients discontinued ANK because of lack or loss of 
efficacy. ¶ Levels of Evidence according to the Oxford Centre for Evidence-based Medicine 
(March 2009). 
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